DUBLIN–(BUSINESS WIRE)–The “Minerva-35
– Drug Insight, 2019” report has been added to ResearchAndMarkets.com’s
offering.
Minerva-35 – Drug Insight, 2019 highlights the drug marketed
details and the Global API Manufacturers details across the globe along
with the location. The report covers the Global Market Assessment of the
Minerva-35 covering the historical global sales and also provides the
Minerva-35 sales estimation during the forecasted period (2019-2021).
The report also covers the patents information and market exclusivity
data, route of synthesis, market competition, and API manufacturers by
country. In addition to this, the report also provides the SWOT analysis
for Minerva-35 and emerging therapies in this space.
Scope
-
A review of the Minerva-35, based on information derived from company
and industry-specific sources -
Product details on the basis of MOA, target, dosage, route of
administration, molecule type, strength, Chemical type and ATC
Classification - Coverage of the Drug Master Files and API Manufacturers by country
- Patent Expiry Timeline and Exclusivity Details
- Route of Synthesis of the API
- Forecasted Sales Figure from 2019-2021
- Market competition and emerging therapies
- SWOT Analysis
Reasons to Buy
- Establish a comprehensive understanding of Minerva-35
-
Access to drug’s API manufacturers details to devise API procurement
strategy for generic development -
Plan developmental timelines around drug’s patents for the major
markets – US and EU -
Understand Minerva-35’s current and future growth through its
historical and forecasted sales - Identify and understand the current in-market competitors for the drug
-
Identify the product attributes and use it for target finding, drug
repurposing, and precision medicine -
Identify and plan ahead for prospective emerging players and their
products operating in the same space as the drug -
Identify opportunities in the same area as Minerva-35 with the SWOT
analysis
Key Topics Covered
1. Report Introduction
2. Minerva-35 – Overview
- Product Description
- Route of Synthesis
- Mechanism of Action
- Pharmacology
- Pharmacodynamics
- Pharmacokinetics
- Adverse Reactions
- Regulatory Milestones by Region
- Deals and Partnerships
3. Product Details
4. Minerva-35 Sales Assessment
- Historical Sales
- Forecasted Sales
5. Patent Details
6. Global API Manufacturers Assessment
- Active Pharmaceutical Ingredient (API) Manufacturers by Country
- Active Pharmaceutical Ingredient (API) Manufacturers by Region
7. Market Competition
8. Emerging Therapies
- Product Description
- Research and Development
- Product Development Activities
9. SWOT Analysis
For more information about this report visit https://www.researchandmarkets.com/r/un4wqe
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Women’s
Health